Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 561

1.

Inflammation and Apparent Treatment-Resistant Hypertension in Patients With Chronic Kidney Disease.

Chen J, Bundy JD, Hamm LL, Hsu CY, Lash J, Miller ER 3rd, Thomas G, Cohen DL, Weir MR, Raj DS, Chen HY, Xie D, Rao P, Wright JT Jr, Rahman M, He J.

Hypertension. 2019 Apr;73(4):785-793. doi: 10.1161/HYPERTENSIONAHA.118.12358.

PMID:
30776971
2.

Lipids, Apolipoproteins, and Risk of Atherosclerotic Cardiovascular Disease in Persons With CKD.

Bajaj A, Xie D, Cedillo-Couvert E, Charleston J, Chen J, Deo R, Feldman HI, Go AS, He J, Horwitz E, Kallem R, Rahman M, Weir MR, Anderson AH, Rader DJ; CRIC Study Investigators.

Am J Kidney Dis. 2019 Jan 24. pii: S0272-6386(18)31158-2. doi: 10.1053/j.ajkd.2018.11.010. [Epub ahead of print]

PMID:
30686529
3.

Influence of Renal Function on the Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety of Non-Vitamin K Antagonist Oral Anticoagulants.

Weir MR, Kreutz R.

Mayo Clin Proc. 2018 Oct;93(10):1503-1519. doi: 10.1016/j.mayocp.2018.06.018. Review.

4.

Use of Renin-Angiotensin System Blockade in Advanced CKD: An NKF-KDOQI Controversies Report.

Weir MR, Lakkis JI, Jaar B, Rocco MV, Choi MJ, Kramer HJ, Ku E.

Am J Kidney Dis. 2018 Dec;72(6):873-884. doi: 10.1053/j.ajkd.2018.06.010. Epub 2018 Sep 7.

PMID:
30201547
5.

Albuminuria and Allograft Failure, Cardiovascular Disease Events, and All-Cause Death in Stable Kidney Transplant Recipients: A Cohort Analysis of the FAVORIT Trial.

Weiner DE, Park M, Tighiouart H, Joseph AA, Carpenter MA, Goyal N, House AA, Hsu CY, Ix JH, Jacques PF, Kew CE, Kim SJ, Kusek JW, Pesavento TE, Pfeffer MA, Smith SR, Weir MR, Levey AS, Bostom AG.

Am J Kidney Dis. 2019 Jan;73(1):51-61. doi: 10.1053/j.ajkd.2018.05.015. Epub 2018 Jul 20.

PMID:
30037726
6.

Obesity and Kidney Disease.

Lakkis JI, Weir MR.

Prog Cardiovasc Dis. 2018 Jul - Aug;61(2):157-167. doi: 10.1016/j.pcad.2018.07.005. Epub 2018 Jul 5. Review.

PMID:
29981350
7.

The Reply.

Weinrauch LA, D'Elia JA, Weir MR, Bunnapradist S, Finn PV, Liu J, Claggett B, Monaco AP.

Am J Med. 2018 Aug;131(8):e349-e351. doi: 10.1016/j.amjmed.2018.04.003. Epub 2018 Jun 19. No abstract available.

PMID:
29934217
8.

Long-term effects of patiromer for hyperkalaemia treatment in patients with mild heart failure and diabetic nephropathy on angiotensin-converting enzymes/angiotensin receptor blockers: results from AMETHYST-DN.

Pitt B, Bakris GL, Weir MR, Freeman MW, Lainscak M, Mayo MR, Garza D, Zawadzki R, Berman L, Bushinsky DA.

ESC Heart Fail. 2018 Aug;5(4):592-602. doi: 10.1002/ehf2.12292. Epub 2018 May 16.

9.

Smoking and outcomes in kidney transplant recipients: a post hoc survival analysis of the FAVORIT trial.

Weinrauch LA, Claggett B, Liu J, Finn PV, Weir MR, Weiner DE, D'Elia JA.

Int J Nephrol Renovasc Dis. 2018 Apr 27;11:155-164. doi: 10.2147/IJNRD.S161001. eCollection 2018.

10.

Effectiveness of informational decision aids and a live donor financial assistance program on pursuit of live kidney transplants in African American hemodialysis patients.

Boulware LE, Ephraim PL, Ameling J, Lewis-Boyer L, Rabb H, Greer RC, Crews DC, Jaar BG, Auguste P, Purnell TS, Lamprea-Monteleagre JA, Olufade T, Gimenez L, Cook C, Campbell T, Woodall A, Ramamurthi H, Davenport CA, Choudhury KR, Weir MR, Hanes DS, Wang NY, Vilme H, Powe NR.

BMC Nephrol. 2018 May 3;19(1):107. doi: 10.1186/s12882-018-0901-x.

11.

Association of Pulse Wave Velocity With Chronic Kidney Disease Progression and Mortality: Findings From the CRIC Study (Chronic Renal Insufficiency Cohort).

Townsend RR, Anderson AH, Chirinos JA, Feldman HI, Grunwald JE, Nessel L, Roy J, Weir MR, Wright JT Jr, Bansal N, Hsu CY; CRIC Study Investigators.

Hypertension. 2018 Jun;71(6):1101-1107. doi: 10.1161/HYPERTENSIONAHA.117.10648. Epub 2018 Apr 30.

PMID:
29712736
12.

Risk of Ischemic Stroke in Patients Newly Diagnosed With Heart Failure: Focus on Patients Without Atrial Fibrillation.

Berger JS, Peterson E, Laliberté F, Germain G, Lejeune D, Schein J, Lefebvre P, Zhao Q, Weir MR.

J Card Fail. 2018 Mar 27. pii: S1071-9164(18)30129-5. doi: 10.1016/j.cardfail.2018.03.012. [Epub ahead of print]

13.

Prevalent and Incident Heart Failure in Cardiovascular Outcome Trials of Patients With Type 2 Diabetes.

Greene SJ, Vaduganathan M, Khan MS, Bakris GL, Weir MR, Seltzer JH, Sattar N, McGuire DK, Januzzi JL, Stockbridge N, Butler J.

J Am Coll Cardiol. 2018 Mar 27;71(12):1379-1390. doi: 10.1016/j.jacc.2018.01.047. Epub 2018 Mar 10. Review.

PMID:
29534825
14.

Hyperkalemia in the Hypertensive Patient.

Lakkis JI, Weir MR.

Curr Cardiol Rep. 2018 Mar 1;20(2):12. doi: 10.1007/s11886-018-0954-2. Review.

PMID:
29492706
15.

Central Blood Pressure and Cardiovascular Outcomes in Chronic Kidney Disease.

Rahman M, Hsu JY, Desai N, Hsu CY, Anderson AH, Appel LJ, Chen J, Cohen DL, Drawz PE, He J, Qiang P, Ricardo AC, Steigerwalt S, Weir MR, Wright JT Jr, Zhang X, Townsend RR; CRIC Study Investigators.

Clin J Am Soc Nephrol. 2018 Apr 6;13(4):585-595. doi: 10.2215/CJN.08620817. Epub 2018 Feb 23.

PMID:
29475992
16.

Cystatin C Is a Gender-Neutral Glomerular Filtration Rate Biomarker in Patients with Cirrhosis.

Mindikoglu AL, Opekun AR, Mitch WE, Magder LS, Christenson RH, Dowling TC, Weir MR, Seliger SL, Howell CD, Raufman JP, Rana A, Goss JA, Khaderi SA, Vierling JM.

Dig Dis Sci. 2018 Mar;63(3):665-675. doi: 10.1007/s10620-017-4897-z. Epub 2018 Feb 1.

17.

Calcium channel blockade and survival in recipients of successful renal transplant: an analysis of the FAVORIT trial results.

Weinrauch LA, Liu J, Claggett B, Finn PV, Weir MR, D'Elia JA.

Int J Nephrol Renovasc Dis. 2017 Dec 22;11:1-7. doi: 10.2147/IJNRD.S148517. eCollection 2018.

18.

Unique metabolomic signature associated with hepatorenal dysfunction and mortality in cirrhosis.

Mindikoglu AL, Opekun AR, Putluri N, Devaraj S, Sheikh-Hamad D, Vierling JM, Goss JA, Rana A, Sood GK, Jalal PK, Inker LA, Mohney RP, Tighiouart H, Christenson RH, Dowling TC, Weir MR, Seliger SL, Hutson WR, Howell CD, Raufman JP, Magder LS, Coarfa C.

Transl Res. 2018 May;195:25-47. doi: 10.1016/j.trsl.2017.12.002. Epub 2017 Dec 12.

PMID:
29291380
19.

Evaluation of clinical outcomes among nonvalvular atrial fibrillation patients treated with rivaroxaban or warfarin, stratified by renal function
.

Weir MR, Haskell L, Berger JS, Ashton V, Laliberté F, Crivera C, Brown K, Lefebvre P, Schein J.

Clin Nephrol. 2018 May;89(5):314-329. doi: 10.5414/CN109281.

PMID:
29231162
20.

Effect of Patiromer on Hyperkalemia Recurrence in Older Chronic Kidney Disease Patients Taking RAAS Inhibitors.

Weir MR, Bushinsky DA, Benton WW, Woods SD, Mayo MR, Arthur SP, Pitt B, Bakris GL.

Am J Med. 2018 May;131(5):555-564.e3. doi: 10.1016/j.amjmed.2017.11.011. Epub 2017 Nov 26.

21.

A Comparison of the Safety and Efficacy of HX575 (Epoetin Alfa Proposed Biosimilar) with Epoetin Alfa in Patients with End-Stage Renal Disease.

Weir MR, Pergola PE, Agarwal R, Fink JC, Kopyt NP, Singh AK, Kumar J, Schmitt S, Schaffar G, Rudy A, McKay JP, Kanceva R.

Am J Nephrol. 2017;46(5):364-370. doi: 10.1159/000481736. Epub 2017 Oct 30.

PMID:
29084409
22.

Patiromer Lowers Serum Potassium When Taken without Food: Comparison to Dosing with Food from an Open-Label, Randomized, Parallel Group Hyperkalemia Study.

Pergola PE, Spiegel DM, Warren S, Yuan J, Weir MR.

Am J Nephrol. 2017;46(4):323-332. doi: 10.1159/000481270. Epub 2017 Oct 11.

23.

Infection and Malignancy Outweigh Cardiovascular Mortality in Kidney Transplant Recipients: Post Hoc Analysis of the FAVORIT Trial.

Weinrauch LA, D'Elia JA, Weir MR, Bunnapradist S, Finn PV, Liu J, Claggett B, Monaco AP.

Am J Med. 2018 Feb;131(2):165-172. doi: 10.1016/j.amjmed.2017.08.038. Epub 2017 Sep 21.

PMID:
28943384
24.

The Author Replies.

Weir MR.

Kidney Int. 2017 Oct;92(4):1016-1017. doi: 10.1016/j.kint.2017.05.029. No abstract available.

PMID:
28938939
25.

Does diabetes impact therapeutic immunomodulation therapy decisions for kidney transplant recipients? Data from the Folic Acid for Vascular Outcome Reduction in Transplant (FAVORIT) trial.

Weinrauch LA, D'Elia JA, Weir MR, Bunnapradist S, Finn P, Liu J, Claggett B, Monaco AP.

Int J Nephrol Renovasc Dis. 2017 Aug 18;10:233-242. doi: 10.2147/IJNRD.S139901. eCollection 2017.

26.

Impact of Hyperuricemia on Long-term Outcomes of Kidney Transplantation: Analysis of the FAVORIT Study.

Kalil RS, Carpenter MA, Ivanova A, Gravens-Mueller L, John AA, Weir MR, Pesavento T, Bostom AG, Pfeffer MA, Hunsicker LG.

Am J Kidney Dis. 2017 Dec;70(6):762-769. doi: 10.1053/j.ajkd.2017.06.013. Epub 2017 Aug 9.

PMID:
28801121
27.

Association of QT-Prolonging Medication Use in CKD with Electrocardiographic Manifestations.

Snitker S, Doerfler RM, Soliman EZ, Deo R, St Peter WL, Kramlik S, Fischer MJ, Navaneethan S, Delafontaine P, Jaar BG, Ojo A, Makos GK, Slaven A, Weir MR, Zhan M, Fink JC; for CRIC Study Investigators.

Clin J Am Soc Nephrol. 2017 Aug 9;12(9). pii: CJN.12991216. doi: 10.2215/CJN.12991216. Print 2017 Sep 7.

28.

Habitual sleep and kidney function in chronic kidney disease: the Chronic Renal Insufficiency Cohort study.

Knutson KL, Lash J, Ricardo AC, Herdegen J, Thornton JD, Rahman M, Turek N, Cohan J, Appel LJ, Bazzano LA, Tamura MK, Steigerwalt SP, Weir MR, Van Cauter E; Cric Study Investigators.

J Sleep Res. 2018 Apr;27(2):281-289. doi: 10.1111/jsr.12573. Epub 2017 Jun 23.

PMID:
28643350
29.

Impact of renal function on ischemic stroke and major bleeding rates in nonvalvular atrial fibrillation patients treated with warfarin or rivaroxaban: a retrospective cohort study using real-world evidence.

Weir MR, Berger JS, Ashton V, Laliberté F, Brown K, Lefebvre P, Schein J.

Curr Med Res Opin. 2017 Oct;33(10):1891-1900. doi: 10.1080/03007995.2017.1339674. Epub 2017 Jul 11.

PMID:
28590785
30.

Evaluation of the Potential for Drug Interactions With Patiromer in Healthy Volunteers.

Lesko LJ, Offman E, Brew CT, Garza D, Benton W, Mayo MR, Romero A, Du Mond C, Weir MR.

J Cardiovasc Pharmacol Ther. 2017 Sep;22(5):434-446. doi: 10.1177/1074248417691135. Epub 2017 Feb 13.

31.

Design of the Magnetic Resonance Imaging Evaluation of Mineralocorticoid Receptor Antagonism in Diabetic Atherosclerosis (MAGMA) Trial.

Rajagopalan S, Alaiti MA, Broadwater K, Goud A, Gaztanaga J, Connelly K, Fares A, Shirazian S, Kreatsoulas C, Farkouh M, Dobre M, Fink JC, Weir MR.

Clin Cardiol. 2017 Sep;40(9):633-640. doi: 10.1002/clc.22718. Epub 2017 May 26.

32.

Expert Panel Recommendations for the Identification and Management of Hyperkalemia and Role of Patiromer in Patients with Chronic Kidney Disease and Heart Failure.

Rafique Z, Weir MR, Onuigbo M, Pitt B, Lafayette R, Butler J, Lopes M, Farnum C, Peacock WF.

J Manag Care Spec Pharm. 2017 Apr;23(4-a Suppl):S10-S19. doi: 10.18553/jmcp.2017.23.4-a.s10.

33.

Lipidomic Signature of Progression of Chronic Kidney Disease in the Chronic Renal Insufficiency Cohort.

Afshinnia F, Rajendiran TM, Karnovsky A, Soni T, Wang X, Xie D, Yang W, Shafi T, Weir MR, He J, Brecklin CS, Rhee EP, Schelling JR, Ojo A, Feldman H, Michailidis G, Pennathur S.

Kidney Int Rep. 2016 Nov;1(4):256-268. doi: 10.1016/j.ekir.2016.08.007. Epub 2016 Aug 18. Erratum in: Kidney Int Rep. 2017 Sep 18;2(6):1265.

34.

Histological Evolution of BK Virus-Associated Nephropathy: Importance of Integrating Clinical and Pathological Findings.

Drachenberg CB, Papadimitriou JC, Chaudhry MR, Ugarte R, Mavanur M, Thomas B, Cangro C, Costa N, Ramos E, Weir MR, Haririan A.

Am J Transplant. 2017 Aug;17(8):2078-2091. doi: 10.1111/ajt.14314. Epub 2017 Jun 6.

35.

Risks of Adverse Events in Advanced CKD: The Chronic Renal Insufficiency Cohort (CRIC) Study.

Grams ME, Yang W, Rebholz CM, Wang X, Porter AC, Inker LA, Horwitz E, Sondheimer JH, Hamm LL, He J, Weir MR, Jaar BG, Shafi T, Appel LJ, Hsu CY; CRIC Study Investigators.

Am J Kidney Dis. 2017 Sep;70(3):337-346. doi: 10.1053/j.ajkd.2017.01.050. Epub 2017 Mar 30.

36.

Cell-Free DNA and Active Rejection in Kidney Allografts.

Bloom RD, Bromberg JS, Poggio ED, Bunnapradist S, Langone AJ, Sood P, Matas AJ, Mehta S, Mannon RB, Sharfuddin A, Fischbach B, Narayanan M, Jordan SC, Cohen D, Weir MR, Hiller D, Prasad P, Woodward RN, Grskovic M, Sninsky JJ, Yee JP, Brennan DC; Circulating Donor-Derived Cell-Free DNA in Blood for Diagnosing Active Rejection in Kidney Transplant Recipients (DART) Study Investigators.

J Am Soc Nephrol. 2017 Jul;28(7):2221-2232. doi: 10.1681/ASN.2016091034. Epub 2017 Mar 9.

37.

Acute changes in glomerular filtration rate with renin-angiotensin system (RAS) inhibition: clinical implications.

Weir MR.

Kidney Int. 2017 Mar;91(3):529-531. doi: 10.1016/j.kint.2016.11.019.

PMID:
28202167
38.

Effectiveness of patiromer in the treatment of hyperkalemia in chronic kidney disease patients with hypertension on diuretics.

Weir MR, Mayo MR, Garza D, Arthur SA, Berman L, Bushinsky D, Wilson DJ, Epstein M.

J Hypertens. 2017 May;35 Suppl 1:S57-S63. doi: 10.1097/HJH.0000000000001278.

39.

Early Kidney Allograft Dysfunction (Threatened Allograft): Comparative Effectiveness of Continuing Versus Discontinuation of Tacrolimus and Use of Sirolimus to Prevent Graft Failure: A Retrospective Patient-Centered Outcome Study.

Wali RK, Prentice HA, Reddivari V, Baffoe-Bonnie G, Drachenberg CI, Pappadimitriou JC, Ramos E, Cooper M, Jonsson J, Bartlett S, Weir MR.

Transplant Direct. 2016 Aug 11;2(9):e98. eCollection 2016 Sep.

40.

Effect of Patiromer on Urinary Ion Excretion in Healthy Adults.

Bushinsky DA, Spiegel DM, Gross C, Benton WW, Fogli J, Hill Gallant KM, Du Mond C, Block GA, Weir MR, Pitt B.

Clin J Am Soc Nephrol. 2016 Oct 7;11(10):1769-1776. doi: 10.2215/CJN.01170216. Epub 2016 Sep 27.

41.

Non-GFR Determinants of Low-Molecular-Weight Serum Protein Filtration Markers in CKD.

Liu X, Foster MC, Tighiouart H, Anderson AH, Beck GJ, Contreras G, Coresh J, Eckfeldt JH, Feldman HI, Greene T, Hamm LL, He J, Horwitz E, Lewis J, Ricardo AC, Shou H, Townsend RR, Weir MR, Inker LA, Levey AS; CRIC (Chronic Renal Insufficiency Cohort) Study Investigators.

Am J Kidney Dis. 2016 Dec;68(6):892-900. doi: 10.1053/j.ajkd.2016.07.021. Epub 2016 Sep 20.

42.

Biomarkers for Predicting Improved Outcomes With Renal Artery Stenting.

Weir MR.

Hypertension. 2016 Nov;68(5):1098-1099. Epub 2016 Sep 19. No abstract available.

PMID:
27647846
43.

The Tyranny of Generic Immunosuppressants.

Ravichandran B, Weir MR.

Am J Nephrol. 2016;44(3):204-5. doi: 10.1159/000449022. Epub 2016 Aug 31. No abstract available.

44.

Rivaroxaban in Chronic Hemodialysis Patients: Clarification of an Editorial Error.

Dias C, Moore KT, Murphy J, Ariyawansa J, Smith W, Mills RM, Weir MR.

Am J Nephrol. 2016;44(2):169. doi: 10.1159/000448817. Epub 2016 Aug 23. No abstract available.

45.

Abnormalities in biomarkers of mineral and bone metabolism in kidney donors.

Kasiske BL, Kumar R, Kimmel PL, Pesavento TE, Kalil RS, Kraus ES, Rabb H, Posselt AM, Anderson-Haag TL, Steffes MW, Israni AK, Snyder JJ, Singh RJ, Weir MR.

Kidney Int. 2016 Oct;90(4):861-8. doi: 10.1016/j.kint.2016.05.012. Epub 2016 Jun 28.

46.

Treatment with patiromer decreases aldosterone in patients with chronic kidney disease and hyperkalemia on renin-angiotensin system inhibitors.

Weir MR, Bakris GL, Gross C, Mayo MR, Garza D, Stasiv Y, Yuan J, Berman L, Williams GH.

Kidney Int. 2016 Sep;90(3):696-704. doi: 10.1016/j.kint.2016.04.019. Epub 2016 Jun 24.

47.

Late intervention with the small molecule BB3 mitigates postischemic kidney injury.

Narayan P, Duan B, Jiang K, Li J, Paka L, Yamin MA, Friedman SL, Weir MR, Goldberg ID.

Am J Physiol Renal Physiol. 2016 Aug 1;311(2):F352-61. doi: 10.1152/ajprenal.00455.2015. Epub 2016 Jun 1.

48.

Diabetic ketoacidosis, sodium glucose transporter-2 inhibitors and the kidney.

Palmer BF, Clegg DJ, Taylor SI, Weir MR.

J Diabetes Complications. 2016 Aug;30(6):1162-6. doi: 10.1016/j.jdiacomp.2016.05.008. Epub 2016 May 10. Review.

PMID:
27240541
49.

Pharmacokinetics, Pharmacodynamics, and Safety of Single-Dose Rivaroxaban in Chronic Hemodialysis.

Dias C, Moore KT, Murphy J, Ariyawansa J, Smith W, Mills RM, Weir MR.

Am J Nephrol. 2016;43(4):229-36. doi: 10.1159/000445328. Epub 2016 Apr 22. Erratum in: Am J Nephrol. 2016;44(2):170.

50.

AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY POSITION STATEMENT ON THE ASSOCIATION OF SGLT-2 INHIBITORS AND DIABETIC KETOACIDOSIS.

Handelsman Y, Henry RR, Bloomgarden ZT, Dagogo-Jack S, DeFronzo RA, Einhorn D, Ferrannini E, Fonseca VA, Garber AJ, Grunberger G, LeRoith D, Umpierrez GE, Weir MR.

Endocr Pract. 2016 Jun;22(6):753-62. doi: 10.4158/EP161292.PS. Epub 2016 Jun 1.

PMID:
27082665

Supplemental Content

Support Center